An Adult Spasticity Registry of OnabotulinumtoxinA Treatment (ASPIRE)

Allergan

Status: Completed

Conditions: Muscle Spasticity

Treatments: Drug: onabotulinumtoxinA

Study type: Observational

Funder types: Industry

Identifiers

NCT01930786

GMA-BTX-SP-12-001

Details and patient eligibility

About

This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.

Enrollment: 744 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment with onabotulinumtoxinA according to the decision of the physician for spasticity
• Willingness to complete study questionnaires and answer study questions by phone or internet

Exclusion criteria

• Concurrent participation in a clinical trial for spasticity

Trial design

744 participants in 1 patient group

onabotulinumtoxinA

Description:

onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.

Treatment:

Drug: onabotulinumtoxinA